ProCE Banner Activity

DLBCL: Biology, Prognosis, and Selection of Initial Therapy

Slideset Download
Download these slides from a live symposium at ASH 2022 to gain more insight into the biology, prognosis, and selection of initial therapy for patients with DLBCL.

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Laurie H. Sehn

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Bristol Myers Squibb

Genmab US Inc and AbbVie

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada